Skip to main content
. 2018 Feb 26;9(21):15591–15605. doi: 10.18632/oncotarget.24570

Figure 3. Anti-cancer effect of M-PTX in human squamous cell carcinoma.

Figure 3

(A) Anti-cancer effect of M-PTX. OSC-19 (human squamous cell carcinoma) and HSC-3 (human squamous cell carcinoma) were cultured in the presence of 1.9, 3.8, 7.5 or 15 µM M-PTX. Anti-cancer effect was analyzed by means of XTT assays in comparison with that of intact PTX (n = 4, ***p < 0.001 vs. control). (B) Cell apoptosis rate was assessed by FACS detection. M-PTX induced apoptosis in OSC-19 cells (n = 4, *p < 0.05, **p < 0.01) and HSC-3 cells (n = 6, *p < 0.05 vs. control) in a dose-dependent manner (0, 7.5, 15 or 30 μM) for 6 hours. (C) Effect of M-PTX on ROS production in OSC-19 and HSC-3. M-PTX generated ROS in a concentration-dependent manner for 24 hours (n = 4, *p < 0.05, **p < 0.01, ***p < 0.001 vs. control). (D) Cell cycle analysis. The cell cycles of OSC-19 and HSC-3 cells were analyzed at 6-hours intervals in the presence or absence of M-PTX. M-PTX retained the characteristic anti-cancer mechanism of PTX, i.e., induction of G2/M arrest (n = 4, *p < 0.05).